Default company panoramic image

Qualiber, Inc.

We are transforming existing FDA approved therapeutics and making them more effective and less toxic, improving outcomes for cancer patients

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chapel Hill, NC, USA
  • Currency USD
  • Founded April 2010
  • Employees 3
  • Website

Company Summary

Qualiber has developed a novel drug delivery nanotechnology (nanoCLIPD) that has the potential to transform existing (previously FDA approved) therapeutics across multiple disease areas. We are developing more effective and less toxic therapeutics for cancer using this drug delivery platform consequently providing greater clinical benefit and longer survival to patients.


  • Default avatar
    Anil K Goyal, Ph.D.
    President and CEO

    • >20 years at venture-backed and public biotechnology companies.
    • Led business development, marketing, licensing, mergers/acquisitions and technology development for drugs and diagnostics.
    • Co-founded Qualiber, Inc. in 2010.
    • Head of BizDev @ Ascletis, Inc., a Hangzhou, China specialty/pharma.
    • Management experience includes roles at Optherion, Serenex, Millennium Pharmaceuticals, Genome Therapeutics Corporation and Merck & Co.

  • Default avatar
    Leaf Huang, Ph.D.
    Co-Founder and CSO

    • 30+ years of drug delivery R&D experience with liposome drugs & gene-delivery
    • Recipient of The Alec D. Bangham Achievement Award in liposome research
    • Founder of 4 other companies: PDS Biotech, Lipella, Lipogen, Rgene Therapeutics